Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioVie Inc.
  6. Company
    BIVI   US09074F2074

BIOVIE INC.

(BIVI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
BioVie Inc. clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.
Managers
Name Title Age Since
Cuong Viet Do President, Chief Executive Officer & Director 54 2021
Joanne Wendy Kim Chief Financial Officer & Secretary - 2018
Patrick Yeramian, Dr. Chief Medical Officer - 2018
James D. Lang Independent Director 55 2016
Michael Sherman Independent Director 61 2017
Richard J. Berman Independent Director 77 2019
Robert Joseph Hariri Gordon, Dr. Independent Director 61 2020
Steven Gorlin, Dr. Independent Director 82 2020
Sigmund Rogich Independent Director 76 2020
Jonathan Adams Executive Vice President-Liver Disease Program 57 2021
Members of the board
Name Title Age Since
Terren Peizer Chairman 60 2021
Cuong Viet Do President, Chief Executive Officer & Director 54 2021
James D. Lang Independent Director 55 2016
Michael Sherman Independent Director 61 2017
Richard J. Berman Independent Director 77 2019
Robert Joseph Hariri Gordon, Dr. Independent Director 61 2020
Steven Gorlin, Dr. Independent Director 82 2020
Sigmund Rogich Independent Director 76 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 24,833,324 4,932,734 19.9% 0 0.0% 19.9%
Shareholders
NameEquities%
Terren Peizer 19,529,846 78.6%
Cuong Viet Do 199,054 0.80%
The Vanguard Group, Inc. 97,021 0.39%
Columbia Management Investment Advisers LLC 72,280 0.29%
Jonathan Adams 63,674 0.26%
swisspartners AG 55,521 0.22%
Steve Gorlin 50,000 0.20%
Renaissance Technologies LLC 27,900 0.11%
James D. Lang 25,044 0.10%
Millennium Management LLC 23,107 0.093%
Company contact information
BioVie, Inc.
2120 Colorado Avenue
Suite 230
Santa Monica, CA 90404

Phone : +1.312.283.5793
Web : http://www.bioviepharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of BioVie Inc.
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
BIOVIE INC.-67.67%139
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610
BEIGENE, LTD.46.63%35 360
GENMAB A/S21.44%30 583
ARGENX SE3.14%14 957
ACCELERON PHARMA INC.35.96%10 637
MIRATI THERAPEUTICS, INC.-13.36%9 823
NEUROCRINE BIOSCIENCES, INC.8.02%9 800
HUALAN BIOLOGICAL ENGINEERING INC.-29.17%8 549
ASCENDIS PHARMA A/S-13.29%8 225
LEGEND BIOTECH CORPORATION88.49%7 060
SAREPTA THERAPEUTICS, INC.-52.94%6 976
GW PHARMACEUTICALS PLC89.72%6 907
ARROWHEAD PHARMACEUTICALS, INC.-13.95%6 884
EXELIXIS, INC.6.63%6 742
REMEGEN CO., LTD.7.68%6 446
KODIAK SCIENCES INC.-21.04%5 938